Lilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody's

November 23, 2016 11:41 AM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Moody's Investor Service commented that Eli Lilly and Company's (NYSE: LLY) announcement that its experimental Alzheimer's disease drug solanezumab did not meet the endpoint in a Phase III trial is credit negative. There is no effect on Lilly's A2 rating or stable rating outlook.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Credit Ratings

Add Your Comment